6. Glycemic Targets: Standards of Medical Care in Diabetes—2019
The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Abstract
The American Diabetes Association (ADA) “Standards of Medical Care in Diabetes” includes ADA’s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA’s clinical practice recommendations, please refer to the Standards of Care Introduction. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751 · cited 1×
“pharmacotherapy) and in all-cause mortality (13% and 27%, respectively) (22).”
BackgroundIntensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518 · cited 1×
“If the patient is meeting A1C target, consider one of three strategies (39):”
Background
Cited by
Items 201–300 of 687
Zhong, P., Zeng, H., Huang, M., He, G., & Chen, Z. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.695182 · Cited by 27
Hypoglycaemia and its management in primary care setting
Ibrahim, M., Baker, J., Cahn, A., Eckel, R. H., El Sayed, N. A., Fischl, A. H., Gaede, P., Leslie, R. D., Pieralice, S., Tuccinardi, D., et al. (2020) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3332 · Cited by 21
Severe hypoglycemia and the risk of end stage renal disease in type 2 diabetes
Yun, J., Park, Y., Han, K., Kim, H.-W., Cha, S., Ahn, Y., & Ko, S. (2021) · Scientific Reports · doi:10.1038/s41598-021-82838-5 · Cited by 24
Oluwajuyitan, T. D., Ijarotimi, O. S., & Fagbemi, T. N. (2022) · Food Frontiers · doi:10.1002/fft2.133 · Cited by 24
Lajara, R. (2019) · Postgraduate Medicine · doi:10.1080/00325481.2019.1670017 · Cited by 23
Characterization of Fibroblasts in Iatrogenic Laryngotracheal Stenosis and Type II Diabetes Mellitus
Lina, I. A., Tsai, H., Ding, D., Davis, R. J., Motz, K., & Hillel, A. T. (2020) · The Laryngoscope · doi:10.1002/lary.29026 · Cited by 21
Pinsker, J. E., Bartee, A., Katz, M., Lalonde, A., Jones, R., Dassau, E., & Wolpert, H. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0619 · Cited by 21
den Braber, N., Vollenbroek-Hutten, M. M. R., Westerik, K. M., Bakker, S. J. L., Navis, G. J., van Beijnum, B.-J. F., & Laverman, G. D. (2021) · Diabetes Care · doi:10.2337/dc20-2241 · Cited by 21
Oluwajuyitan, T. D., Ijarotimi, O. S., & Fagbemi, T. N. (2021) · Clinical Phytoscience · doi:10.1186/s40816-021-00327-8 · Cited by 26
Flores-Hernández, M. N., Martínez-Coria, H., López-Valdés, H. E., Arteaga-Silva, M., Arrieta-Cruz, I., & Gutiérrez-Juárez, R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252010959 · Cited by 20
“Continuous monitoring of blood glucose concentrations also plays an important role in evaluating the efficacy and safety of T2DM treatment [10,11].”
BackgroundPai, Y.-W., Tang, C.-L., Lin, C.-H., Lin, S.-Y., Lee, I.-T., & Chang, M.-H. (2021) · Diabetes & Metabolism · doi:10.1016/j.diabet.2020.04.004 · Cited by 20
Glucagon Therapy: A Comparison of Current and Novel Treatments
Sherman, J. J., & Lariccia, J. L. (2020) · Diabetes Spectrum · doi:10.2337/ds19-0076 · Cited by 21
Mathiesen, A. S., Rothmann, M. J., Zoffmann, V., Jakobsen, J. C., Gluud, C. N., Lindschou, J., Due‐Christensen, M., Rasmussen, B., Marqvorsen, E. H. S., & Thomsen, T. (2021) · Systematic Reviews · doi:10.1186/s13643-020-01566-5 · Cited by 20
Demidova, T. Y., & Kozhevnikov, A. A. (2020) · Diabetes Mellitus · doi:10.14341/dm10273 · Cited by 20
Buckeridge, C., Tsamandouras, N., Carvajal‐Gonzalez, S., Brown, L. S., Hernandez‐Illas, M., & Saxena, A. R. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15643 · Cited by 20
Evaluation of a comprehensive diabetic foot ulcer care quality model
Schechter, M. C., Fayfman, M., Khan, L. S., Carr, K. R., Patterson, S., Ziemer, D. C., Umpierrez, G. E., Rajani, R. R., & Kempker, R. R. (2020) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2019.107516 · Cited by 22
Therapeutic inertia in patients with type 2 diabetes treated with non-insulin agents
Ampudia‐Blasco, F. J., Palanca, A., Trillo-Mata, J. L., Navarro, J., & Real, J. T. (2021) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2020.107828 · Cited by 20
Diabetes mellitus type 1 in adults
Dedov, I. I., Shestakova, M. V., Mayorov, A. Y., Шамхалова, М. Ш., Nikonova, T. V., Sukhareva, O. Y., Пекарева, Е. В., Ibragimova, L. I., Mikhina, M. S., Galstyan, G. R., et al. (2020) · Diabetes Mellitus · doi:10.14341/dm12505 · Cited by 22
Hu, Y., Shen, Y., Yan, R., Li, F.-F., Ding, B., Wang, H., Su, X., & Ma, J. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00879-x · Cited by 22
Automated Insulin Delivery: Easy Enough to Use in Primary Care?
HEILE, M. K., Hollstegge, B., Broxterman, L., Cai, A., & Close, K. L. (2020) · Clinical Diabetes · doi:10.2337/cd20-0050 · Cited by 19
“Diabetes Association general A1C goal of,7% between 2016 and 2018 (4), and only 37% of adults reached”
BackgroundThe epidemiology of diabetes in the Waikato region: an analysis of primary care data
Chepulis, L. M., Morison, B. J., Keenan, R., Paul, R. G., Lao, C., & Lawrenson, R. A. (2021) · Journal of Primary Health Care · doi:10.1071/hc20067 · Cited by 22
Lin, Y., Zhang, Y., Shen, X., Huang, L., & Yan, S. (2021) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2021.107926 · Cited by 21
Improving Management of Type 2 Diabetes Using Home-Based Telemonitoring: Cohort Study
Milani, R. V., Chava, P., Wilt, J. K., Entwisle, J., Karam, S., Burton, J. H., & Blonde, L. (2021) · JMIR Diabetes · doi:10.2196/24687 · Cited by 20
Pathophysiology and management of hypoglycemia in diabetes
RANGEL, E. S., Deajon-Jackson, J. D., & Hwang, J. J. (2022) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14904 · Cited by 21
Suzuki, D., Yamada, H., Yoshida, M., Funazaki, S., Amamoto, M., Morimoto, J., & Hara, K. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13240 · Cited by 20
Almeida, M. L., Duarte, P. M., Figueira, E. A., Lemos, J. C., Nobre, C. M. G., Miranda, T. S., & Gurgel, B. C. D. V. (2019) · Clinical Oral Investigations · doi:10.1007/s00784-019-02927-8 · Cited by 19
Bettencourt‐Silva, R., Aguiar, B., Araújo, V., Barreira, R., Guedes, V., Ribeiro, M. J., Carvalho, D. M., Östlundh, L., & Paulo, M. S. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-028604 · Cited by 18
Lin, Y., Huang, Y., Chen, H., Hsieh, S., Sun, J., Chen, S., & Lin, C.-H. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-00707-x · Cited by 19
Alzahrani, A. M., Zaidi, A. A. A., Alzahrani, S. M., Binmahfouz, S. A., & Farahat, F. M. (2020) · Journal of Family and Community Medicine · doi:10.4103/jfcm.jfcm_142_19 · Cited by 18
Use of flash glucose monitoring for post-bariatric hypoglycaemia diagnosis and management
Lobato, C. B., Pereira, S. S., Guimarães, M., Morais, T., Oliveira, P. F., de Carvalho, J. P. M., Nora, M. C., & Monteiro, M. P. (2020) · Scientific Reports · doi:10.1038/s41598-020-68029-8 · Cited by 18
Malekzadeh, H., Lotfaliany, M., Ostovar, A., Hadaegh, F., Azizi, F., Yoosefi, M., Farzadfar, F., & Khalili, D. (2020) · Scientific Reports · doi:10.1038/s41598-020-68640-9 · Cited by 19
Tamez-Pérez, H. E., Author, D., Cantú-Santos, O. M., Gutiérrez-González, D., González-Facio, R., & Romero-Ibarguengoitia, M. E. (2021) · Journal of Diabetes Science and Technology · doi:10.1177/19322968211034533 · Cited by 21
Nicchio, I. G., Cirelli, T., Nepomuceno, R., Hidalgo, M. A. R., Rossa, C., Cirelli, J. A., Orrico, S. R. P., Barros, S. P., Theodoro, L. H., & Scarel‐Caminaga, R. M. (2021) · Journal of Diabetes Research · doi:10.1155/2021/1049307 · Cited by 18
“The following biochemical parameters in the peripheral blood were determined for each participant: differential red and white blood cell count (ABX Micros 60); glycemic profile: insulin (chemiluminescence method), fasting glucose (modified Bondar and Mead method, Labtest Kit), and HbA1c (turbidimetric inhibition immun…”
MethodDjonor, S. K., Ako-Nnubeng, I. T., Owusu, E. D. A., Akuffo, K. O., Nortey, P., Agyei‐Manu, E., & Danso‐Appiah, A. (2021) · PLoS ONE · doi:10.1371/journal.pone.0261455 · Cited by 19
Jafari, A., Moshki, M., Naddafi, F., Ghelichi-Ghojogh, M., Armanmehr, V., Kazemi, K., & Nejatian, M. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2024.1421053 · Cited by 20
“In Iran, approximately five million adults developed diabetes in 2017, and it is estimated that by 2030, 9.2 million people will have the disease (3, 5).”
BackgroundInfluentialPetroni, M. L., Montesi, L., Colosimo, S., Caletti, M. T., Mazzotti, A., & Marchesini, G. (2019) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.82 · Cited by 19
Nauck, M. A., Lindmeyer, A. M., Mathieu, C., & Meier, J. J. (2019) · Journal of Diabetes Science and Technology · doi:10.1177/1932296819882752 · Cited by 17
Jackson, I. L., Onung, S. I., & Oiwoh, E. P. (2020) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2020.12.027 · Cited by 17
Kamal, M. M., Adel, A., Sayed, G. H., Ragab, S. H., & Kassem, D. H. (2020) · Translational research · doi:10.1016/j.trsl.2020.12.004 · Cited by 17
Giménez‐Pérez, G., Franch‐Nadal, J., Ortega, E., Mata‐Cases, M., Goday, A., Real, J., Rodríguez, Á., Vlacho, B., & Mauricio, D. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10071536 · Cited by 19
A Type 2 Diabetes Subtype Responsive to ACCORD Intensive Glycemia Treatment
Mariam, A., Miller-Atkins, G. A., Pantalone, K. M., Zimmerman, R. S., Barnard, J., Kattan, M. W., Shah, H., McLeod, H. L., Doria, A., Wagner, M. J., et al. (2021) · Diabetes Care · doi:10.2337/dc20-2700 · Cited by 19
Atkin, S. L., Butler, A. E., Hunt, S. C., & Kilpatrick, E. S. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14449 · Cited by 20
Hsing, S.-C., Lin, C. S., Chen, J., Chen, Y., & Fang, W. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11080799 · Cited by 17
“5% for older adults was suggested in the practical guidelines [20].”
BackgroundUse of herbal medicine for diabetes mellitus in adults from the central–western region of Mexico
Ruíz‐Noa, Y., Ibarra‐Reynoso, L. D. R., Ruiz-Padilla, A. J., Alonso‐Castro, Á. J., Ramírez‐Morales, M. A., Zapata‐Morales, J. R., Castellanos, L. M. O., Solorio‐Alvarado, C. R., & Lara-Morales, A. (2021) · Primary care diabetes · doi:10.1016/j.pcd.2021.08.010 · Cited by 17
Lin, Y., Shao, H., Shi, L., Anderson, A. H., & Fonseca, V. A. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14806 · Cited by 18
Glucose profiles in obstructive sleep apnea and type 2 diabetes mellitus
Aurora, R. N., Gaynanova, I., Patel, P. S., & Punjabi, N. M. (2022) · Sleep Medicine · doi:10.1016/j.sleep.2022.04.007 · Cited by 19
Abrahim, A. M., Tilahun, T., & Gelana, B. (2023) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s412529 · Cited by 18
Kahsay, H., Fantahun, B., Nedi, T., & Demoz, G. T. (2019) · Journal of Diabetes Research · doi:10.1155/2019/9037374 · Cited by 20
Haldrup, S., Lapolla, A., Gundgaard, J., & Wolden, M. L. (2019) · Journal of Medical Economics · doi:10.1080/13696998.2019.1669613 · Cited by 17
Stantonyonge, N., Sampedro, F., Méndez, J., Martínez‐Horta, S., Chico, A. I., & Gómez‐Ansón, B. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa832 · Cited by 16
Sun, K., Liu, S., Liu, J., Ding, Z., Jiang, Y., Zhang, J., Chen, H., Yu, J., Wu, C., & Chiu, D. T. (2021) · Analytical Chemistry · doi:10.1021/acs.analchem.0c04223 · Cited by 17
Holst, J. J., & Madsbad, S. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01032-y · Cited by 17
Otieno, F. C. F., Mikhail, T., Acharya, K., Muga, J., Ngugi, N., & Njenga, E. (2021) · Endocrine and Metabolic Science · doi:10.1016/j.endmts.2021.100093 · Cited by 16
Bailey, T. S., Willard, J., Klaff, L. J., Stone, J. Y., Melgaard, A. E., & Tehranchi, R. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14475 · Cited by 16
The efficacy of pioglitazone for renal protection in diabetic kidney disease
Ho, C.-C., Yang, Y., Huang, C., Lo, S., Wang, Y., & Kornelius, E. (2022) · PLoS ONE · doi:10.1371/journal.pone.0264129 · Cited by 18
Managing Severe Hypoglycaemia in Patients with Diabetes: Current Challenges and Emerging Therapies
Demirbilek, H., Vurallı, D., Haris, B., & Hussain, K. (2023) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s313837 · Cited by 23
Yan, L., Li, L., Peng, Y. D., Song, G., Ye, S., Du, L. Y., Hou, J. N., & Ji, Q. H. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0646-y · Cited by 17
Personalized Management of Type 2 Diabetes
Peter, P. R., & Lupsa, B. C. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1244-0 · Cited by 17
Veroneze, R., Corbi, S. C. T., da Silva, B. R., Rocha, C. S., Maurer‐Morelli, C. V., Orrico, S. R. P., Cirelli, J. A., Zuben, F. J. V., & Scarel‐Caminaga, R. M. (2020) · PLoS ONE · doi:10.1371/journal.pone.0240269 · Cited by 16
Aranishi, T., Nagai, Y., Takita, Y., Zhang, S., & Nishimura, R. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-00711-1 · Cited by 16
Quality performance and associated factors in Swiss diabetes care – A cross-sectional study
Meier, R., Valeri, F., Senn, O., Rosemann, T. J., & Chmiel, C. (2020) · PLoS ONE · doi:10.1371/journal.pone.0232686 · Cited by 15
Belay, D. M., Bayih, W. A., Alemu, A. Y., Endalamaw, A., Mekonen, D. K., Ayele, A. S., Belayneh, W. H., Tegared, H. A., & Birhane, B. M. (2020) · PLoS ONE · doi:10.1371/journal.pone.0241811 · Cited by 18
Uncooked cornstarch for the prevention of hypoglycemic events
Pepa, G. D., Vetrani, C., Lupoli, R., Massimino, E., Lembo, E., Riccardi, G., & Capaldo, B. (2021) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2020.1864617 · Cited by 19
Porcellati, F., Mauro, S. D., Mazzieri, A., Scamporrino, A., Filippello, A., Fano, M. D., Fanelli, C. G., Purrello, F., Malaguarnera, R., & Piro, S. (2021) · Biomolecules · doi:10.3390/biom11091281 · Cited by 19
Bideberi, A. T., & Mutagaywa, R. (2022) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s347765 · Cited by 16
Sun, Z., Hu, Y., Yu, C., Guo, Y., Pang, Y., Sun, D., Pei, P., Yang, L., Chen, Y., Du, H., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac264 · Cited by 15
Mahrouqi, A. S. A., Mallinson, R. K., Oh, K. M., & Weinstein, A. A. (2022) · International Journal of Nursing Practice · doi:10.1111/ijn.13103 · Cited by 18
Pais, R., Cariou, B., Noureddin, M., Francque, S., Schattenberg, J. M., Abdelmalek, M. F., Lalazar, G., Varma, S., Dietrich, J., Miller, V., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.03.014 · Cited by 15
RSSDI consensus recommendations on insulin therapy in the management of diabetes
(extended), E. P., Chawla, R., Makkar, B. M., Aggarwal, S., Bajaj, S., Das, A. K., Ghosh, S. K., Gupta, A., Gupta, S., Jaggi, S., et al. (2019) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-019-00783-6 · Cited by 16
SMITH, L. B., Foster, N. C., Bollepalli, S., Fitterman-Harris, H. F., & Rancourt, D. (2019) · Journal of Pediatric Psychology · doi:10.1093/jpepsy/jsz090 · Cited by 16
Turgeon, R. D., Koshman, S. L., Youngson, E. R. E., & Pearson, G. J. (2019) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2359 · Cited by 15
Adams, J. A., Banderas, V., Lopez, J. R., & Sackner, M. A. (2020) · Journal of Diabetes Research · doi:10.1155/2020/8317973 · Cited by 15
Patoulias, D., Katsimardou, A., Kalogirou, M., Zografou, I., Toumpourleka, M., Imprialos, K. P., Stavropoulos, K., Stergiou, I., Papadopoulos, C. E., & Doumas, M. N. (2020) · Diabetes & Metabolism · doi:10.1016/j.diabet.2020.04.001 · Cited by 15
Lindmeyer, A. M., Meier, J. J., & Nauck, M. A. (2020) · Journal of Diabetes Science and Technology · doi:10.1177/1932296820949939 · Cited by 15
Will oral semaglutide be a game-changer in the management of type 2 diabetes in primary care?
Seidu, S., Mellbin, L., Kaiser, M., & Khunti, K. (2020) · Primary care diabetes · doi:10.1016/j.pcd.2020.07.011 · Cited by 14
Chen, S., Zhu, Y., Jin, S., Zhao, D., Guo, J., Chen, L., & Huang, Y. (2023) · BMC Cardiovascular Disorders · doi:10.1186/s12872-023-03478-3 · Cited by 18
“Thus, we chose an HbA1c level of 7% as it represents the optimal cutoff associated with the management of diabetes in previous studies and corresponds with the target for glycemic control set by the American Diabetes Association [16].”
MethodAga, F., Dunbar, S. B., Kebede, T., Higgins, M. K., & GARY, R. A. (2020) · Nursing Open · doi:10.1002/nop2.517 · Cited by 15
“Hyperglycaemia is an important risk factor for CVD events and all-cause mortality in people with T2D (Afsharian et al., 2016; Takao, Suka, Yangisawa, & Iwamoto, 2017).”
BackgroundMise en place de l’insulinothérapie automatisée en boucle fermée : position d’experts français
Franc, S., Schaepelynck, P., Tubiana‐Rufi, N., Chaillous, L., Joubert, M., Renard, É., Reznik, Y., Abettan, C., Bismuth, É., Beltrand, J., et al. (2020) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(20)30003-1 · Cited by 24
Diabetic retinopathy in the Eastern Morocco: Different stage frequencies and associated risk factors
Hammoudi, J., Bouanani, N. E. H., Chelqi, E. H., Bentata, Y., Nouayti, H., Legssyer, A., & Ziyyat, A. (2020) · Saudi Journal of Biological Sciences · doi:10.1016/j.sjbs.2020.11.010 · Cited by 14
“…was defined according to the criteria of the WHO classification of 1999 (Chalmers et al., 1999), by a value of systolic blood pressure 140 mmHg and / or a diastolic blood pressure 90 mmHg. 4- Glycated hemoglobin (HbA1c) (HbA1c 7.0% was considered as a good glycemic control (ADA, 2019)).”
MethodInfluentialLatimer, J. M., Roll, K. L., Daubert, D. M., Zhang, H., Shalev, T., collaborators, A. S., Wolff, L. F., & Kotsakis, G. A. (2021) · Journal of Periodontology · doi:10.1002/jper.21-0015 · Cited by 18
Oh, S., Purja, S., Shin, H., Kim, M., & Kim, E. Y. (2022) · Diabetes and Vascular Disease Research · doi:10.1177/14791641221106866 · Cited by 14
Beverly, E. A., Ritholz, M. D., Rennie, R. G., & Mort, S. C. (2019) · BMC Medical Education · doi:10.1186/s12909-019-1615-x · Cited by 14
Herold, Z., Herold, M., Nagy, P., Patócs, A., Doleschall, M., & Somogyi, A. (2019) · Journal of Diabetes Investigation · doi:10.1111/jdi.13203 · Cited by 14
Lv, Q., Shen, J., Miao, L., Ye, B., Schepers, C., Plat, A. W., & Shi, Y. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00819-9 · Cited by 16
Battelino, T., Edelman, S. V., Nishimura, R., & Bergenstal, R. M. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0180 · Cited by 13
Musa, I. R., Omar, S. M., Sharif, M. E., Ahmed, A. B. A., & Adam, I. (2021) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.23873 · Cited by 11
Cho, Y. K., Lee, J., Kim, H. S., Park, J., Jung, C. H., & Lee, W. J. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00881-3 · Cited by 14
Khalili, S., Moradi, O., Kharazmi, A. B., Raoufi, M., Sistanizad, M., & Shariat, M. (2020) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2020.10.014 · Cited by 17
Papathanassiou, E., Papaioannou, A. Ι., Papanikolaou, I. C., Antonakis, E., Makou, I., Hillas, G., Mizi, E., Bakakos, P., Apollonatou, V., Verykokou, G., et al. (2021) · COPD Journal of Chronic Obstructive Pulmonary Disease · doi:10.1080/15412555.2021.1902491 · Cited by 13
You, N., Pan, H., Zeng, Y., Lü, P., Zhu, L., Lu, W., Liu, Q., & Martínez, L. (2021) · Scientific Reports · doi:10.1038/s41598-021-90664-y · Cited by 13
Moin, A. S. M., Sathyapalan, T., Atkin, S. L., & Butler, A. E. (2022) · Metabolites · doi:10.3390/metabo12030196 · Cited by 16
Tezera, R., Sahile, Z., Yilma, D., Misganaw, E., Amare, E., & Haidar, J. (2022) · PLoS ONE · doi:10.1371/journal.pone.0265523 · Cited by 15
“If the fasting blood glucose is between 80–130 mg/dl considered as controlled glycemic level; if fasting blood glucose is either less than 80mg/dl or greater than 130mg/dl considered as a poorly controlled glycemic level [37].”
BackgroundAlqunai, M. S., & Alrashid, F. F. (2022) · PubMed · Cited by 22
Campbell, D. B., Sobol, C. G., Stacy, M. R., Atway, S. A., Teng, X., Haurani, M. J., & Go, M. R. (2023) · Annals of Vascular Surgery · doi:10.1016/j.avsg.2023.10.018 · Cited by 13
Kim, Y. T., Chung, H. J., Park, B. R., Kim, Y. Y., Lee, J. H., Kang, D. R., Kim, J., Lee, M. Y., & Lee, J. Y. (2020) · Hypertension · doi:10.1161/hypertensionaha.120.15320 · Cited by 13
Performance of an Automated Insulin Delivery System: Results of Early Phase Feasibility Studies
Christiansen, M. P., Bartee, A. K., Lalonde, A., Jones, R. E., Katz, M. L., Wolpert, H. A., & Brazg, R. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0318 · Cited by 13
Validation of the Lebanese Medication Adherence Scale among Lebanese diabetic patients
Ibrahim, L. I., Ibrahim, L., Hallit, S. R., Salameh, P., Sacre, H., Akel, M., Serhal, R. B., & Saleh, N. (2020) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-020-01197-9 · Cited by 13
Bai, F., Chen, J., Pandey, D. K., Durazo-Arvizú, R., Talavera, G. A., Allison, M., Perreira, K. M., Schneiderman, N., Sutherland, M. W., Cai, J., et al. (2021) · Stroke · doi:10.1161/strokeaha.120.031216 · Cited by 13
Dietary protein sources and risk of diabetic nephropathy in women: A case-control study
Aziz, M., Jalilpiran, Y., Nekouimehr, M., Fattahi, S., Mokhtari, P., Jayedi, A., Yekaninejad, M. S., & Mirzaei, K. (2021) · BMC Endocrine Disorders · doi:10.1186/s12902-021-00841-3 · Cited by 14
High concurrent use of sulfonylureas and antimicrobials with drug interactions causing hypoglycemia
Pilla, S. J., Pitts, S. I., & Maruthur, N. M. (2022) · Journal of Patient Safety · doi:10.1097/pts.0000000000000739 · Cited by 12
Metadata
- Authors
- American Diabetes Association
- Corresponding author
- American Diabetes Association
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2018-12-07
- Volume
- 42
- Issue
- Supplement_1
- Pages
- S61-S70
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W4250208868
- Cited by
- 655
- References
- 59
- Citations by year
- 2026: 17 · 2025: 27 · 2024: 35 · 2023: 57 · 2022: 85 · 2021: 117 · 2020: 202 · 2019: 112
- FWCI
- 16.65
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- glycemic targets, glycemic control, diabetes management, clinical guidelines, quality of care, treatment goals
- MeSH terms
- Blood Glucose, Diabetes Mellitus, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Societies, Medical, United States, Practice Guidelines as Topic, Standard of Care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.